Clinical trial · no report yet · Phase 1/Phase 2
SIMONE
Saci Nivo Rela for TNBC
- NCT06963905 ↗
- Recruiting
- Yale University
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase Ib Randomized Open-label Trial of Sacituzumab Govitecan Plus Nivolumab or Sacituzumab Govitecan Plus Nivolumab and Relatlimab as Second-line Therapy for Patients With Metastatic Triple Negative Breast Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Triple-negative Breast Cancer
- Interventions
- Relatlimab FDC + Nivolumab; Sacituzumab Govitecan (SG); Nivolumab
- Arms
- Arm A · Active comparator
- Arm B · Active comparator
- Enrollment
- 60 (estimated)
- Primary outcomes
- Incidence and severity of dose limiting toxicities in patients treated with sacituzumab govitecan combinations
- Sponsor
- Yale University with Bristol-Myers Squibb
- Start
- Dec 29, 2025
- Primary completion
- Dec 2030 (estimated)
- Results posted
- No
- Registry record
- NCT06963905 · updated May 22, 2026